Clinical Trials Browser

Phase 2 × Not yet recruiting × Thyroid Carcinoma, Anaplastic × Clear all

NCT07470489 2026-04-16

Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer

Phase 2 Not yet recruiting

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic